Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 to 65

Traditional Chinese oral solution and mouthwash to shorten severe radiation-induced mouth sores in head and neck cancer.

Official title: Chinese Herbal Oral Solution and Mouthwash Shorten the Duration of Severe Radiotherapy-induced Oral Mucositis in Patients With Head and Neck Malignancies.

Run by West China Hospital · NCT07339774 · Data updated 2026-11-12

This trial will try a combined traditional Chinese oral solution and mouthwash to shorten and ease severe radiation-induced mouth sores in adults receiving radiotherapy for head and neck cancer.

More Radiation-induced Oral Mucositis trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment128 (estimated)
SponsorWest China Hospital
Academic / other
Drugs / interventionsradiation
Locations1 site (Chengdu, Sichuan)
StatusRecruiting
StartedNovember 5, 2026
Main results expectedMay 31, 2027
Study endsAugust 30, 2027
Registry record updatedNovember 6, 2026
Trial IDNCT07339774 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–65 with non-metastatic head and neck cancer undergoing radiotherapy (or concurrent chemoradiotherapy) who develop RTOG grade ≥3 oral mucositis, have ECOG ≤2, and adequate organ function.

Probably not a fit

Patients with prior head and neck radiotherapy, active severe periodontal disease, recent use of antibiotics/antifungals or antimicrobial mouthwash, planned therapy with EGFR inhibitors or immune checkpoint inhibitors, multiple drug allergies, or other serious comorbidities may not benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized phase 2 trial enrolls adults with non-metastatic head and neck cancer who develop severe radiation-induced oral mucositis (RTOG grade ≥3) during radiotherapy. Participants start treatment the first day severe mucositis appears and receive Zishui Daohuo oral solution three times daily plus Kuju mouthwash six times daily, or matched placebos. Treatment continues until two weeks after radiotherapy, and patients are asked to avoid eating, drinking, or oral hygiene for one hour after each use to maximize mucosal contact. Primary outcomes include duration of severe mucositis and safety/adverse events compared between the TCM combination and placebo groups.

Why it matters

Potential benefit: If successful, the regimen could shorten time with severe mouth sores, reduce pain, and help patients complete radiotherapy with better oral comfort.

How similar studies have gone: Some small trials of topical or herbal preparations have suggested benefit for radiation mucositis, but high-quality evidence for this specific TCM combination is limited and further testing is needed.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patients pathologically diagnosed with non-metastatic head and neck malignant tumors;
2. Age range: 18 to 65 years old (including 18 and 65 years old);
3. Eastern Cooperative Oncology Group performance status of ≤2;
4. Radiotherapy or concurrent chemoradiotherapy is required;
5. The main organ functions well;
6. Sign informed consent.

Exclusion Criteria:

1. Allergic constitution (such as those known to be allergic to two or more drugs);
2. Patients who plan to use drugs that can cause or worsen oral mucosal inflammation (such as anti EGFR monoclonal antibodies, immune checkpoint inhibitors, etc.) after the start of radiotherapy;
3. Use of antibiotics, antifungal drugs, or antimicrobial mouthwash within 1 month of the study;
4. Poor oral hygiene and/or severe periodontal diseases;
5. History of head and neck radiotherapy;
6. Deemed unsuitable for the study by the investigators (concomitant with any other severe diseases).

Where it's running

  • West China Hospital
    Chengdu, Sichuan, China
    Recruiting

Study contacts

  • Principal investigator: Xingchen Peng, Professor — West China Hospital
  • Study coordinator: Xingchen Peng Professor
  • Email: pxx2014@163.com
  • Phone: +8618980606753

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.